NASDAQ: PHVS
Pharvaris Nv Stock Forecast, Predictions & Price Target

Analyst price target for PHVS

Based on 2 analysts offering 12 month price targets for Pharvaris Nv

Min Forecast
$42.00+120.24%
Avg Forecast
$44.00+130.73%
Max Forecast
$46.00+141.22%

Should I buy or sell PHVS stock?

Based on 2 analysts offering ratings for Pharvaris Nv.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PHVS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PHVS as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have trailed the market by -8.02%. Learn More

Be the first to know when Wall Street analysts revise their PHVS stock forecasts and price targets.

PHVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-19
lockedlocked$00.00+00.00%2024-09-06

1 of 1

Forecast return on equity

Is PHVS forecast to generate an efficient return?

Company
-38.22%
Industry
136.29%
Market
70.65%
PHVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHVS forecast to generate an efficient return on assets?

Company
-36.22%
Industry
22.71%
PHVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHVS earnings per share forecast

What is PHVS's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.67
Avg 2 year Forecast
-$3.03
Avg 3 year Forecast
-$2.86

PHVS revenue forecast

What is PHVS's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$18.8M
Avg 2 year Forecast
$56.5M
Avg 3 year Forecast
$234.5M

PHVS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHVS$19.07$44.00+130.73%Strong Buy
LENZ$36.95$37.00+0.14%Strong Buy
GYRE$11.51N/AN/A
AVBP$29.26$37.25+27.31%Strong Buy
COGT$8.89$15.60+75.48%Buy

Pharvaris Nv Stock Forecast FAQ

Is Pharvaris Nv Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PHVS) stock is to Strong Buy PHVS stock.

Out of 2 analysts, 1 (50%) are recommending PHVS as a Strong Buy, 1 (50%) are recommending PHVS as a Buy, 0 (0%) are recommending PHVS as a Hold, 0 (0%) are recommending PHVS as a Sell, and 0 (0%) are recommending PHVS as a Strong Sell.

If you're new to stock investing, here's how to buy Pharvaris Nv stock.

What is PHVS's earnings growth forecast for 2024-2026?

(NASDAQ: PHVS) Pharvaris Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.31%.

Pharvaris Nv's earnings in 2024 is -$140,647,060.On average, 5 Wall Street analysts forecast PHVS's earnings for 2024 to be -$144,585,458, with the lowest PHVS earnings forecast at -$166,495,632, and the highest PHVS earnings forecast at -$131,786,445. On average, 5 Wall Street analysts forecast PHVS's earnings for 2025 to be -$164,217,842, with the lowest PHVS earnings forecast at -$170,834,281, and the highest PHVS earnings forecast at -$158,902,998.

In 2026, PHVS is forecast to generate -$155,106,680 in earnings, with the lowest earnings forecast at -$171,918,943 and the highest earnings forecast at -$126,905,466.

What is PHVS's revenue growth forecast for 2026-2028?

(NASDAQ: PHVS) Pharvaris Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.

Pharvaris Nv's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast PHVS's revenue for 2026 to be $1,019,473,908, with the lowest PHVS revenue forecast at $626,229,663, and the highest PHVS revenue forecast at $1,412,772,385. On average, 2 Wall Street analysts forecast PHVS's revenue for 2027 to be $3,065,797,426, with the lowest PHVS revenue forecast at $990,296,497, and the highest PHVS revenue forecast at $5,141,298,354.

In 2028, PHVS is forecast to generate $12,717,391,957 in revenue, with the lowest revenue forecast at $9,238,609,437 and the highest revenue forecast at $16,196,174,477.

What is PHVS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PHVS) forecast ROA is -36.22%, which is lower than the forecast US Biotechnology industry average of 22.71%.

What is PHVS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PHVS price target, the average PHVS price target is $44.00, with the highest PHVS stock price forecast at $46.00 and the lowest PHVS stock price forecast at $42.00.

On average, Wall Street analysts predict that Pharvaris Nv's share price could reach $44.00 by Sep 19, 2025. The average Pharvaris Nv stock price prediction forecasts a potential upside of 130.73% from the current PHVS share price of $19.07.

What is PHVS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: PHVS) Pharvaris Nv's current Earnings Per Share (EPS) is -$2.77. On average, analysts forecast that PHVS's EPS will be -$2.67 for 2024, with the lowest EPS forecast at -$3.07, and the highest EPS forecast at -$2.43. On average, analysts forecast that PHVS's EPS will be -$3.03 for 2025, with the lowest EPS forecast at -$3.15, and the highest EPS forecast at -$2.93. In 2026, PHVS's EPS is forecast to hit -$2.86 (min: -$3.17, max: -$2.34).

What is PHVS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PHVS) forecast ROE is -38.22%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.